Advancements in the radiooncological treatment of high-risk prostate cancer: a quarter century of achievements

Abstract

Background The aim of the study was to evaluate the development of treatment of primary high-risk prostate cancer in regards to biochemical no evidence of disease (bNED), acute and late gastrointestinal (GI) and genitourinary (GU) side effects. Patients and methods Primary high-risk prostate cancer patients treated between 1994 and 2016 were included. Applied doses ranged from 60 to 80 Gy, with a dose of 1.8 or 2 Gy per fraction. Techniques were either 3D conformal or intensity modulated radiotherapy and volumetric intensity modulated arc therapy. Results 142 patients were treated with doses up to 70 Gy (median dose 66 Gy; 66 Gy group), 282 with doses between 70 and 76 Gy (median dose 74 Gy; 74 Gy group), and 141 with doses >76 Gy (median dose 78 Gy; 78 Gy group). The median follow-up was 48 months. The bNED rates were 50% after 5 years and 44% after 9 years in the 66 Gy group; 65% and 54%, respectively, in the 74 Gy group; and 83% and 66%, respectively, in the 78 Gy group (p = 0.03 vs. 74 Gy and p < 0.0001 vs. 66 Gy). We found a higher rate of acute GI side effects in the 78 Gy group compared to the other groups, but not in maximum acute GU side effects and late maximum GI and GU effects. Conclusions High-risk prostate cancer patients treated with doses of 78 Gy had significantly better bNED rates. Compared to the historical 66 Gy group, 50% more patients achieved bNED after a follow-up of 9 years.

Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [177Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside

“…The combinational treatment led to a long-lasting response as evident from undetectable PSA values maintained for nearly five years after PSMA-RLT. The extent of toxicity after IMRT was low and expected for standard fractionation 33 and there was only minor chronic salivary gland toxicity associated with RLT. This promising experience might pave the way for the application of combined elective, large field EBRT, PSMA-RLT and androgen deprivation therapy for local dose escalation in more patients with locally advanced or regional PC.…”

Comparison of treatment costs for primary localized prostate cancer in Austria and Vienna: an economic analysis

“…Therefore, we replaced it with HDG10.01 B (2,134 points for patients >74 years old) and HDG10.01 C (1,381 points for patients ≤74 years old) for prostate cancer. As the median age of patients is <75 years ( 13 – 15 ), we decided to use HDG10.01 C for further calculations.…”

Gene expression signature predicts radiation sensitivity in cell lines using the integral of dose–response curve

“…Radiotherapy (RT) is among the most commonly used therapeutic modes of interventions in the management of cancer [ 1 ]. In routine clinical care, it is known that over half of all patients diagnosed with cancer undergo radiotherapy as a palliative and curative treatment modality in an adjuvant or a neoadjuvant setting [ 2 ].…”